Stock CRDL CARDIOL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cardiol Therapeutics Inc.

Equities

CRDL

CA14161Y2006

Delayed Toronto S.E.
Other stock markets
 11:11:52 2024-04-29 am EDT 		5-day change 1st Jan Change
2.43 CAD -0.82% Intraday chart for Cardiol Therapeutics Inc. -0.41% +120.91%
Apr. 22 HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target MT
Apr. 01 Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cardiol Therapeutics : Notice of Meeting and Record Date - Form 6-K
PU
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
NE
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
NE
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
NE
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
NE
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
NE
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
NE
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
NE
CARDIOL THERAPEUTICS : CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 - Form 6-K
PU
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
NE
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
AQ
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
NE
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
AQ
Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol
AQ
Cardiol Therapeutics : MATERIAL CHANGE REPORT - Form 6-K
PU
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
NE
Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)
AQ
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
AQ
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
NE
Cardiol Therapeutics : MATERIAL CHANGE REPORT - Form 6-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRDL Stock
  4. News Cardiol Therapeutics Inc.
  5. Press Releases